About this trial
The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.
Eligibility criteria
Qualifiers
Systemically healthy males and females ≥18 years old
Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)
Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) > 5 mm, following non-surgical periodontal therapy (NSPT). If >4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.
Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months
Disqualifiers
Teeth with degree III mobility
Multi-rooted teeth with grade ≥2 furcation involvement
Heavy smokers (≥10 cigarettes a day)
Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery
Trial design
Treatments tested in this trial
- Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)
- Periodontal Access Flap (AF)
Treatment groups
Sponsors and collaborators
Queen Mary University of London
Lead sponsor
Geistlich Pharma AG
Collaborator